Organisation paid for research Program year 2025 Source: CMS Open Payments

Rainier Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$11,854,589

2,593 payments

Through program year 2025, Rainier Clinical Research Center is reported as receiving $11,854,589 in research payments, across 2,593 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,282,519 255
2024 Research $1,992,274 118
2023 Research $1,610,549 276
2022 Research $1,817,637 272
2021 Research $1,414,573 1,252
2020 Research $1,943,325 218
2019 Research $1,793,713 202

Breakdown

Who paid Research payments · program years 2019–2025
  1. Abbott Laboratories $3,051,911 630 payments
  2. Senseonics, Incorporated $1,759,140 39 payments
  3. Eli Lilly and Company $1,677,173 72 payments
  4. Roche Diabetes Care, Inc. $1,267,456 32 payments
  5. Medtronic MiniMed, Inc. $726,706 45 payments
  6. Novo Nordisk AS $725,932 1,476 payments
  7. Medtronic, Inc. $716,682 26 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $567,069 51 payments
  9. Pfizer Inc. $295,037 37 payments
  10. Moderna TX, Inc. $255,024 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. PROMISE (A Prospective, Multicenter Evaluation of Accuracy and Safety of an Implantable Continuous Glucose Sensor Lasting up to 180 Days) $1,046,013 26 payments
  2. Senseonics CTP0041 Enhance Study $690,782 11 payments
  3. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $472,566 4 payments
  4. Evaluation of Precision of the GFAP and UCH-L1 Assays in the i-STAT TBI Cartridge Using Whole Blood $395,583 74 payments
  5. Feasibility Study of an Electrochemical Sensor for CGM Development over a 14-day Wearing Period $336,045 4 payments
  6. Cep298 Ewis $323,940 13 payments
  7. Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study Using Venous and/or Ca $300,578 1 payment
  8. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $299,853 3 payments
  9. CIP331 Smart Pen $250,701 5 payments
  10. Phase III efficacy for obesity - without T2DM $248,540 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record